Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827
Araújo A, et al. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803–827
António Araújo
Read
617
Timeswas read the article
353
Total PDF
264
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 July | 5 | 6 | 11 |
| 2024 June | 19 | 26 | 45 |
| 2024 May | 26 | 30 | 56 |
| 2024 April | 18 | 19 | 37 |
| 2024 March | 24 | 14 | 38 |
| 2024 February | 23 | 28 | 51 |
| 2024 January | 15 | 27 | 42 |
| 2023 December | 15 | 20 | 35 |
| 2023 November | 12 | 30 | 42 |
| 2023 October | 12 | 33 | 45 |
| 2023 September | 24 | 30 | 54 |
| 2023 August | 12 | 13 | 25 |
| 2023 July | 17 | 28 | 45 |
| 2023 June | 12 | 14 | 26 |
| 2023 May | 20 | 24 | 44 |
| 2023 April | 10 | 11 | 21 |
Show all
